Vitura Health responds to Federal Court ruling on CDA Clinics QLD Pty Ltd
In an announcement dated 2 November 2026, Vitura Health Limited (ASX: VIT) advised that it is not liable for the $6.5 million pecuniary penalty imposed on CDA Clinics QLD Pty Ltd. The company stated the judgment has no financial impact on Vitura or its other subsidiaries.
On Friday 30 October 2026, Justice Berna Joan Collier found that CDA Clinics QLD Pty Ltd engaged in extensive advertising of cannabidiol (CBD) products in contravention of s 42DLB(1) of the Therapeutic Act 1989 (the TG Act). The penalty therefore sits with that entity rather than on the listed group’s balance sheet.
When big ASX news breaks, our subscribers know first
Key facts at a glance
- Penalty: $6.5 million pecuniary penalty imposed on CDA Clinics QLD Pty Ltd
- Entity status: CDA Clinics QLD Pty Ltd entered into liquidation in January 2025
- Treatment: the pecuniary penalty will be a claim in that liquidation
- Vitura position: the Company is not liable, and there is no financial impact on Vitura or its other subsidiaries
- Conduct period: between 27 April and 30 July 2021
- Personnel: senior individuals involved in the conduct at that time are no longer with the Company
| Item | Detail | Investor relevance |
|---|---|---|
| Ruling date | **30 October 2026** | Federal Court finding by Justice Berna Joan Collier |
| Pecuniary penalty | **$6.5 million**, payable by CDA Clinics QLD Pty Ltd | Vitura states it is not liable |
| Financial impact | **None** on Vitura or its other subsidiaries | Company’s stated position |
| Entity status | In liquidation since **January 2025** | Penalty will be a claim in the liquidation |
Why the liquidation and timing matter for investors
A liquidation is the process of winding up a company and dealing with its creditors. Vitura stated the pecuniary penalty will be a claim in the liquidation of CDA Clinics QLD Pty Ltd, rather than a liability of the Company.
The proceedings relate to conduct between 27 April and 30 July 2021, which predates the January 2025 liquidation. Senior individuals involved in the conduct at that time are no longer with the Company.
Leadership at the group has also turned over since the 2021 conduct period, with the January 2026 CEO transition bringing interim management under Ryan Tattle and Shane Tanner and an early-starting CFO.
For investors, the ruling concerns historical conduct in a separate entity, and Vitura has stated it carries no financial impact for the group.
Vitura’s continuing business
Vitura describes itself as a diversified digital health business. Its subsidiaries and investments include:
- Burleigh Heads Cannabis and Canview: roughly 600 therapeutic product and device SKUs from roughly 70 brands, with roughly 4,700 Australian pharmacies holding accounts on Canview
- Doctors on Demand: a nationwide 24/7 x 365 telehealth platform
- Cortexa: a 50% owned joint venture with PharmAla Biotech (CSE: MDMA)
- Candor Medical: nationwide telehealth consultations
- Flora Holdings (Releaf brand): a 42.5% equity interest
- Cannadoc Health: 75.5% owned
The company’s message is unchanged: the judgment has no financial impact on Vitura or its other subsidiaries.
Get Healthcare News Before the Market Moves
Join 20,000+ investors receiving FREE breaking ASX news within minutes of release, with in-depth analysis already done. Click the “Free Alerts” button at Big News Blast to get healthcare announcements in your inbox the moment they break and stay ahead of the market.